# A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

> **NCT06983743** · PHASE1 · RECRUITING · sponsor: **Erasca, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Solid Tumors

## Interventions

- **DRUG:** ERAS-0015
- **DRUG:** ERAS-0015 in combination

## Key facts

- **NCT ID:** NCT06983743
- **Lead sponsor:** Erasca, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-05
- **Primary completion:** 2028-05-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06983743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06983743, "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06983743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*